For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com  Inclusion Criteria:  Presence of at least one lesion with measurable disease as defined by RECIST v1.1 criteria for response assessment Participants must have received, and then progressed, or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting, if such a therapy exists ECOG status of 0 or 1 Life expectancy of ≥ 12 weeks at the time of informed consent per Investigator assessment  Exclusion Criteria:  Participants with history of severe and/or life-threatening toxicity related to prior immune therapy (eg, anti-CTLA-4 or anti-PD-1/PD-L1 treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) Participants with an active, known or suspected autoimmune disease Participants with primary CNS tumors  Other protocol-defined inclusion/exclusion criteria apply